Web Results
www.targetedonc.com/view/fda-approves-olaparib-for-hrr-mutant-mcrpc

May 19, 2020 ... The FDA has approved olaparib for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or ...

www.onclive.com/view/fda-approves-olaparib-for-hrrmutant-mcrpc

May 19, 2020 ... The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous ...

www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-as-first-line-maintenance-with-bevacizumab-in-advanced-ovarian-cancer-and-grants-priority-review

Lactation: No data are available regarding the presence of olaparib in ... Select patients for therapy based on an FDA-approved companion diagnostic for ...

www.cancernetwork.com/view/fda-approves-olaparib-hrr-gene-mutated-mcrpc

May 20, 2020 ... The FDA approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous ...

www.healio.com/news/hematology-oncology/20200508/fda-expands-lynparza-approval-for-gynecologic-cancer

May 8, 2020 ... The FDA expanded the approval of olaparib to include its use in combination with bevacizumab for first-line maintenance treatment of certain ...

journals.lww.com/oncology-times/fulltext/2015/01250/accelerated_approval_for_olaparib_for_advanced.16.aspx

The Food and Drug Administration has granted accelerated approval to olaparib (Lynparza, made by AstraZeneca) to treat women with advanced ovarian cancer ...

www.astrazeneca-us.com/media/press-releases/2014/lynparza-approved-by-the-us-fda-20141219.html

Dec 19, 2014 ... AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA™ (olaparib) capsules. LYNPARZA is the first ...

ascopost.com/issues/january-25-2020/fda-approves-olaparib-for-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer

Jan 25, 2020 ... The FDA also approved the BRACAnalysis CDx test as a companion diagnostic for the selection of patients with pancreatic cancer for treatment ...

www.oncnursingnews.com/view/fda-approves-olaparib-plus-bevacizumab-for-frontline-maintenance-treatment-of-hrd-ovarian-cancer

May 8, 2020 ... The FDA has approved the combination of olaparib (Lynparza) and bevacizumab (Avastin) for the maintenance treatment of patients with ...

clincancerres.aacrjournals.org/content/21/19/4257

Oct 1, 2015 ... FDA approval of olaparib was primarily based on an open-label, nonrandomized clinical trial in 298 patients with deleterious or suspected ...

www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf

LYNPARZA safely and effectively. See full prescribing information for. LYNPARZA. LYNPARZA® (olaparib) tablets, for oral use. Initial U.S. Approval: 2014.